Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)

NCT00483704 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1935

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraines

Interventions

DRUG: Telcagepant 140 mg
DRUG: Talcagepant 280 mg
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC